Novo Nordisk Keeps 2026 Guidance Intact as FDA Plant Remediation Delays Denecimig

Novo Nordisk holds its 2026 targets after the FDA extended the review of hemophilia A candidate Denecimig; the U.S. launch was not planned before H1 2027.

Novo Nordisk is sticking to its full-year 2026 financial targets, even after U.S. regulators extended their review of the company's hemophilia A antibody candidate Denecimig. The Danish drugmaker said the longer timeline does not weigh on its operating objectives for the year, since the U.S. launch of the treatment was never penciled in before the first half of 2027.

The FDA had originally been expected to rule in the third quarter of 2026. According to Reuters, the extended review stems from ongoing remediation work at a manufacturing site rather than any problem with the drug itself. Novo Nordisk has not confirmed a formal rejection or any additional requests for information from the agency, and no new decision date has been set.

No Safety or Efficacy Concerns Flagged

The company filed its application in September 2025 for adults and children with hemophilia A, both with and without inhibitors. The FDA did not identify deficiencies in the submitted clinical data on efficacy or safety, Novo Nordisk said. While the U.S. process drags on, the drug has moved ahead in Europe: on 17 September, the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion. Final EU market authorization is still pending.

The rare blood disorders unit that Denecimig belongs to carries a clearly defined weight within the group. In the 2025 financial year, Novo Nordisk generated roughly DKK 12.0 billion in revenue from the segment, against group sales of DKK 309 billion at the time. The company says the current plant refurbishments do not affect any other products already on the market, leaving the existing portfolio intact and, in management's view, safeguarding operating earnings power. That buffer helps absorb timing setbacks on individual projects in day-to-day business.

A Bruising Year on the Trading Floor

Investors have had little to cheer about in 2025. The stock closed Friday at EUR 33.06, down 25 percent since the start of the year and 40 percent below its 52-week high. Skepticism was already visible in September, when the market gave a muted reception to the company's capital markets day. Media reports pointed to competition from Eli Lilly, looming patent expirations on semaglutide, and open questions about future pricing power as sources of concern.

To shore up a pipeline beyond its existing blockbusters, management has turned to in-licensing. On 29 September, Novo Nordisk secured worldwide rights outside mainland China, Hong Kong, Macau and Taiwan to an experimental oral drug candidate from Jiangsu Hengrui Pharmaceuticals. The deal for the GLP-1/GIP agonist HRS-1596 includes a USD 300 million upfront payment and could reach a total volume of up to USD 2.6 billion through milestone payments.

Betting on Scale Through 2030

Alongside the licensing push, the group laid out ambitious plans in September running to the end of the decade. By 2030, Novo Nordisk aims to have more than five blockbuster products on the market and to serve over 60 million patients worldwide. At the same time, manufacturing capacity is to be expanded so that ten times as many people with obesity can access oral GLP-1 therapies. The company noted that these targets do not constitute a financial forecast.

With the Denecimig delay, one piece of the U.S. product lineup now shifts to the first half of 2027. As long as the clinical data remain untouched, attention centers on how quickly the regulatory issues at the production facilities can be resolved. A green light from the FDA once the plant work is complete would open the door to the planned launch and give the rare disease division fresh room to grow.